In-house ownership of intellectual property for drug candidates and securing rights in major regions

A theme focused on securing in-house the intellectual property required for the development of SB623, SB618, SB308 and other products, and obtaining basic and use patents in major regions, including the United States, to strengthen product exclusivity and the term of protection.